John Marshall

Summary

Affiliation: Georgetown University
Country: USA

Publications

  1. ncbi request reprint A phase II trial of ISIS 3521 in patients with metastatic colorectal cancer
    John L Marshall
    Vincent T Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC 20007, USA
    Clin Colorectal Cancer 4:268-74. 2004
  2. pmc Vascular Endothelial Growth Factor plus Epidermal Growth Factor Receptor Dual Targeted Therapy in Metastatic Colorectal Cancer: Synergy or Antagonism?
    John L Marshall
    Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA
    J Oncol 2009:937305. 2009
  3. pmc Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety
    Marie K Gurka
    Department of Radiation Oncology, Georgetown University Hospital, Washington, DC 20007, USA
    Radiat Oncol 8:44. 2013
  4. pmc A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors
    John Marshall
    Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA
    Invest New Drugs 31:399-408. 2013
  5. doi request reprint Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer
    John Marshall
    Lombardi Comprehensive Cancer Center, Georgetown University, 3800 Reservoir Road NW, Washington, DC 20007, USA
    Future Oncol 9:271-81. 2013
  6. pmc Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer
    Howard L Kaufman
    The Tumor Immunology Laboratory, Division of Surgical Oncology, Columbia University, New York, NY, USA
    J Transl Med 5:60. 2007
  7. ncbi request reprint Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas
    John L Marshall
    Lombardi Cancer Center, Georgetown University Medical Center, 3800 Reservoir Rd, NW, Washington, DC 20007, USA
    J Clin Oncol 23:720-31. 2005
  8. ncbi request reprint Novel vaccines for the treatment of gastrointestinal cancers
    John L Marshall
    Division of Hematology and Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Oncology (Williston Park) 19:1557-65; discussion 1566, 1568 passim. 2005
  9. ncbi request reprint The role of bevacizumab as first-line therapy for colon cancer
    John Marshall
    Developmental Therapeutics and GI Oncology, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Semin Oncol 32:S43-7. 2005
  10. ncbi request reprint The impact of targeted therapy on the treatment of colorectal cancer
    John L Marshall
    Division of Hematology and Oncology, Lombardi Comprehensive Cancer Center, Washington, DC 20057, USA
    Oncology (Williston Park) 19:19-24. 2005

Detail Information

Publications47

  1. ncbi request reprint A phase II trial of ISIS 3521 in patients with metastatic colorectal cancer
    John L Marshall
    Vincent T Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC 20007, USA
    Clin Colorectal Cancer 4:268-74. 2004
    ..ISIS 3521 demonstrated no clinical activity or target modulation in refractory metastatic CRC...
  2. pmc Vascular Endothelial Growth Factor plus Epidermal Growth Factor Receptor Dual Targeted Therapy in Metastatic Colorectal Cancer: Synergy or Antagonism?
    John L Marshall
    Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA
    J Oncol 2009:937305. 2009
    ..These results suggest that these specific combinations should not be used in first-line mCRC outside investigational studies...
  3. pmc Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety
    Marie K Gurka
    Department of Radiation Oncology, Georgetown University Hospital, Washington, DC 20007, USA
    Radiat Oncol 8:44. 2013
    ..This Pilot study assessed the safety of concurrent full-dose gemcitabine with SBRT for LAPC...
  4. pmc A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors
    John Marshall
    Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA
    Invest New Drugs 31:399-408. 2013
    ..A Phase I study to determine the maximum tolerated dose (MTD) and pharmacokinetics of afatinib (BIBW 2992), a novel irreversible ErbB Family Blocker, administered orally once daily in a 3-week-on/1-week-off dosing schedule...
  5. doi request reprint Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer
    John Marshall
    Lombardi Comprehensive Cancer Center, Georgetown University, 3800 Reservoir Road NW, Washington, DC 20007, USA
    Future Oncol 9:271-81. 2013
    ..To determine the maximum tolerated dose (MTD), safety and anti-tumor activity of afatinib combined with docetaxel in advanced cancer...
  6. pmc Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer
    Howard L Kaufman
    The Tumor Immunology Laboratory, Division of Surgical Oncology, Columbia University, New York, NY, USA
    J Transl Med 5:60. 2007
    ....
  7. ncbi request reprint Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas
    John L Marshall
    Lombardi Cancer Center, Georgetown University Medical Center, 3800 Reservoir Rd, NW, Washington, DC 20007, USA
    J Clin Oncol 23:720-31. 2005
    ..We describe here the first trial in humans of the CEA-TRICOM vaccines (also including an enhancer agonist epitope within the CEA gene)...
  8. ncbi request reprint Novel vaccines for the treatment of gastrointestinal cancers
    John L Marshall
    Division of Hematology and Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Oncology (Williston Park) 19:1557-65; discussion 1566, 1568 passim. 2005
    ..Phase III studies to test these hypotheses are under way...
  9. ncbi request reprint The role of bevacizumab as first-line therapy for colon cancer
    John Marshall
    Developmental Therapeutics and GI Oncology, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Semin Oncol 32:S43-7. 2005
    ..Additionally, the activity of bevacizumab is being evaluated for use in the second-line treatment setting for patients with CRC...
  10. ncbi request reprint The impact of targeted therapy on the treatment of colorectal cancer
    John L Marshall
    Division of Hematology and Oncology, Lombardi Comprehensive Cancer Center, Washington, DC 20057, USA
    Oncology (Williston Park) 19:19-24. 2005
    ....
  11. ncbi request reprint Clinical implications of the mechanism of epidermal growth factor receptor inhibitors
    John Marshall
    Division of Hematology Oncology, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Cancer 107:1207-18. 2006
    ..Although both classes of anti-EGFR agents target the same receptor, substantial distinctions regarding their mechanism significantly affect dosing requirements, toxicity profiles, and their use as combination agents...
  12. ncbi request reprint The development of novel agents for the treatment of colorectal cancer: a critical review of current practice and some suggestions for the future
    John L Marshall
    Department of Hematology and Oncology, Georgetown University s Lombardi Comprehensive Cancer Center, Washington, DC 20057, USA
    Clin Adv Hematol Oncol 5:167-72. 2007
    ..Our current standards for drug development are increasingly problematic, and it is imperative that we develop new expectations and supporting standards in cancer drug development...
  13. ncbi request reprint Risk assessment in Stage II colorectal cancer
    John L Marshall
    Division of Hematology Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Washington, DC 20007, USA
    Oncology (Williston Park) 24:9-13. 2010
    ..In this article, I will describe the current state of defining high- and low-risk disease, which is mainly through histopathologic characteristics, as well as discuss emerging approaches such as molecular markers and genomic profiling...
  14. ncbi request reprint A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors
    J Marshall
    Division of Oncology Hematology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Ann Oncol 15:1274-83. 2004
    ....
  15. ncbi request reprint Phase I study of prolonged infusion Bryostatin-1 in patients with advanced malignancies
    John L Marshall
    Lombardi Cancer Center, Georgetown University Medical Center, Washington DC 20007, USA
    Cancer Biol Ther 1:409-16. 2002
    ..Therefore we performed a phase 1 clinical trial to determine the safety and recommended dose of prolonged infusion Bryostatin-1...
  16. ncbi request reprint Phase I trial of irinotecan and epirubicin in advanced cancer. Preliminary report
    John L Marshall
    Lombardi Cancer Center, Washington, DC 20007, USA
    Oncology (Williston Park) 16:17-9. 2002
    ..Evidence of clinical activity has been observed. Accrual will continue until the maximum tolerated dose can be determined. Other schedules of the combination of irinotecan and epirubicin should be explored...
  17. ncbi request reprint Integrating targeted agents into therapeutic regimens for patients with resectable colorectal cancer
    John L Marshall
    Division of Hematology Oncology, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC 20007, USA
    Clin Colorectal Cancer 7:S63-6. 2008
    ..We are increasingly managing patients with a multidisciplinary approach, a critical element in our success. Biologic therapies will continue to play an important role in the management of these patients...
  18. ncbi request reprint Biologic therapy for colon cancer
    Aiwu Ruth He
    Lombardi Cancer Center, Georgetown University Hospital, Washington, DC 20007, USA
    Clin Adv Hematol Oncol 3:555-61. 2005
    ..Additional preclinical and clinical studies will enable better usage of these biologic agents and lead to the development of new targeted therapies for the treatment of colon cancer...
  19. ncbi request reprint TRICOM: enhanced vaccines as anticancer therapy
    Benjamin Levy
    Lombardi Comprehensive Cancer Center, 3800 Reservoir Rd NW, Washington, DC 20007, USA
    Expert Rev Vaccines 3:397-402. 2004
    ..Through stimulation of cancer-specific T-cell responses, researchers have demonstrated interesting clinical efficacy in addition to the high safety profile in clinical trials...
  20. ncbi request reprint Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies
    Anatoly Dritschilo
    Department of Radiation Medicine, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia 20007
    Clin Cancer Res 12:1251-9. 2006
    ..In this dose escalation study, we evaluated the safety of combined liposomal formulation of raf antisense oligonucleotide (LErafAON) and radiation therapy in patients with advanced malignancies...
  21. ncbi request reprint Carcinoembryonic antigen-based vaccines
    John Marshall
    Department of Developmental Therapeutics, Georgetown University Medical Center, Washington, DC 20007, USA
    Semin Oncol 30:30-6. 2003
    ..1, ICAM-1, and LFA-3) has also stimulated significant T-cell increases. This review summarizes these studies and discusses the role of CEA in cancer immunotherapy...
  22. ncbi request reprint A phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer
    Naiyer A Rizvi
    Developmental Therapeutics Program, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, USA
    Clin Cancer Res 10:1963-70. 2004
    ....
  23. ncbi request reprint Optimum use of biologics and role of maintenance therapy in colon cancer
    John Marshall
    Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 2057, USA
    Semin Oncol 33:S33-5. 2006
    ..Clinical trials involving novel agents as maintenance therapy are needed...
  24. ncbi request reprint Differential expression of carcinoembryonic antigen (CEA) splice variants in whole blood of colon cancer patients and healthy volunteers: implication for the detection of circulating colon cancer cells
    Regina Hampton
    Department of Oncology, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Oncogene 21:7817-23. 2002
    ..g. by RT-PCR). The discovery of a physiologically expressed CEA splice variant might lead to a better understanding of the biological function of CEA and its family members...
  25. ncbi request reprint The standard of care in oncology is unacceptable
    John Marshall
    Lombardi Cancer Center, Georgetown University, Washington, DC, USA
    Oncology (Williston Park) 20:806. 2006
  26. ncbi request reprint The correlation between patient characteristics and expectations of benefit from Phase I clinical trials
    Kevin P Weinfurt
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27715, USA
    Cancer 98:166-75. 2003
    ..The authors examined a range of patient characteristics to determine which factors were associated with greater expectations of benefit from Phase I trials...
  27. ncbi request reprint Improving the toxicity of irinotecan/5-FU/leucovorin: a 21-day schedule
    Jimmy J Hwang
    Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, USA
    Oncology (Williston Park) 17:37-43. 2003
    ....
  28. pmc Stem cells in gastrointestinal cancers
    Aiwu Ruth He
    Division of Hematology Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA
    Dis Markers 24:217-22. 2008
  29. doi request reprint Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: to test or not to test, that is the question
    John F Deeken
    Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, District of Columbia 20007, USA
    Cancer 113:1502-10. 2008
    ..Consequently, these test results are supplementary to clinical judgment, which requires assessing multiple variables that contribute to phenotype to arrive at individual dosing decisions...
  30. doi request reprint Carcinoembryonic antigen as a vaccine target
    Dongmei Wang
    National Cancer Institute, 10 Center Drive, Building 10, Room 12 N226, Bethesda, MD 20892, USA
    Expert Rev Vaccines 7:987-93. 2008
    ..In this review, we will explore just one aspect of our efforts by focusing on vaccines that target carcinoembryonic antigen...
  31. ncbi request reprint Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial
    Anthony F Shields
    Department of Medicine, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA
    Cancer 100:531-7. 2004
    ..The primary endpoint of the study was to determine the objective response rate, and a secondary endpoint was to measure the time to disease progression...
  32. ncbi request reprint Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study
    Charles M Rudin
    The University of Chicago, Chicago, Illinois, USA
    Clin Cancer Res 10:7244-51. 2004
    ..Liposomal formulation may promote better intratumoral AON delivery and inhibit degradation in vivo. We conducted the first clinical evaluation of this concept using a liposomal AON complementary to the c-raf-1 proto-oncogene (LErafAON)...
  33. ncbi request reprint Initial clinical trial of oral TAC-101, a novel retinoic acid receptor-alpha selective retinoid, in patients with advanced cancer
    Naiyer A Rizvi
    Developmental Therapeutics Program, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, USA
    J Clin Oncol 20:3522-32. 2002
    ..The goals of this study were to determine the safety, toxicity, and pharmacokinetics of TAC-101, a novel synthetic retinoic acid receptor-alpha (RAR-alpha) selective retinoid, in patients with advanced cancer...
  34. ncbi request reprint Capecitabine: fulfilling the promise of oral chemotherapy
    Jimmy J Hwang
    Georgetown University Medical Center, Lombardi Cancer Center, Washington DC 20007, USA
    Expert Opin Pharmacother 3:733-43. 2002
    ....
  35. ncbi request reprint Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor
    John L Marshall
    Georgetown University Medical Center Lombardi Cancer Center, Washington, DC 20007, USA
    Invest New Drugs 23:31-7. 2005
    ..The objectives were to determine the maximum tolerated dose (MTD), dose-limiting toxicities, and pharmacokinetic profile of this orally administered agent...
  36. ncbi request reprint Immunologic therapies for gastrointestinal cancers
    Benjamin Levy
    Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA
    Clin Colorectal Cancer 5:37-49. 2005
    ..The scope is focused on the variety of approaches that have been used, citing the clinical data that have been obtained and reviewing future trials...
  37. ncbi request reprint Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101
    Antonius A Miller
    Wake Forest University School of Medicine, Winston Salem, NC 27157 1082, USA
    J Clin Oncol 25:3055-60. 2007
    ..We investigated dose and pharmacokinetics of erlotinib in patients with hepatic dysfunction or renal dysfunction...
  38. ncbi request reprint Combined inhibition of topoisomerases: a phase I. Study of irinotecan and epirubicin
    Jimmy J Hwang
    Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, USA
    Oncology (Williston Park) 17:46-51. 2003
    ..Other toxicities were acceptable and non-dose-limiting. Accrual of patients continues, at level 3A (irinotecan at 75 mg/m2, epirubicin at 25 mg/m2)...
  39. ncbi request reprint Clinical experiences with G17DT in gastrointestinal malignancies
    Aiwu R He
    Vincent T Lombardi Cancer Research Center, Georgetown University Medical Center, Podium Level, Corridor B, 3800 Reservoir Road, NW Washington, DC 20007, USA
    Expert Rev Anticancer Ther 6:487-92. 2006
    ..In total, there is a clear signal of efficacy with this compound, although further testing is required in order for this efficacy to be demonstrated in a manner that will support regulatory approval...
  40. ncbi request reprint Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial
    Mace L Rothenberg
    Vanderbilt Ingram Cancer Center, 777 Preston Research Building, Nashville, TN 37232 6307, USA
    J Clin Oncol 21:2059-69. 2003
    ..In North America, no effective therapy has been available for patients with progressive metastatic colorectal cancer after front-line treatment with irinotecan, bolus fluorouracil (FU), and leucovorin (IFL)...
  41. ncbi request reprint Costimulatory molecules as adjuvants for immunotherapy
    James W Hodge
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1750, USA
    Front Biosci 11:788-803. 2006
    ..This review will focus on the current state of the use of costimulatory molecules as adjuvants for immunotherapy, and in particular, as immunomodulators for cancer vaccines...
  42. ncbi request reprint Targeted therapy for colorectal cancer
    Jimmy Hwang
    Lombardi Comprehensive Cancer Center, 3800 Reservoir Road NW, Washington, DC 20007, USA
    Curr Opin Investig Drugs 7:1062-6. 2006
    ..Data supporting the use of targeted agents in the treatment of colorectal cancer are reviewed, and the "future for potential novel agents and pathways are discussed...
  43. ncbi request reprint Bevacizumab in the treatment of colorectal cancer
    John L Marshall
    Division ofHematology Oncology, Georgetown University Medical Center, Washington, DC, USA
    Clin Adv Hematol Oncol 5:8-9. 2007
  44. ncbi request reprint A phase I trial of depsipeptide (FR901228) in patients with advanced cancer
    John L Marshall
    Georgetown University, 3800 Reservoir Rd, NW, Washington, DC, USA
    J Exp Ther Oncol 2:325-32. 2002
    ..The MTD was defined as 13.3 mg/m2 with dose limiting toxicities being grade 3 thrombocytopenia and fatigue. Depsipeptide can be safely administered when given as a 4-hour infusion and further clinical trials are warranted...
  45. ncbi request reprint Optimizing palliative treatment of metastatic colorectal cancer in the era of biologic therapy
    Axel Grothey
    Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Oncology (Williston Park) 21:553-64, 566; discussion 566-8, 577-8. 2007
    ..Definitive conclusions on the sequence and duration of front-line therapy and the most effective strategy to ameliorate toxicity await results of ongoing prospective clinical trials...
  46. ncbi request reprint Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy
    Leonard B Saltz
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 25:4793-9. 2007
    ..We assessed the safety and efficacy of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy...
  47. ncbi request reprint Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers
    Andrew L Pecora
    Cancer Center at Hackensack University Medical Center, Hackensack, NJ 07601, USA
    J Clin Oncol 20:2251-66. 2002
    ..This phase I study was designed to define the maximum-tolerated dose (MTD) and safety of single and multiple intravenous doses of PV701 as a single agent in patients with cancer...

Research Grants5

  1. CEA BASED VACCINE THERAPY IN PATIENTS WITH ADVANCED CA
    John Marshall; Fiscal Year: 2001
    ..So far, the applicant's experience with the first generation CEA-based vaccines has generated a great deal of excitement, and yet he anticipates even more from the newer vaccine constructs. ..
  2. CEA BASED VACCINE THERAPY IN PATIENTS WITH ADVANCED CA
    John Marshall; Fiscal Year: 2002
    ..So far, the applicant's experience with the first generation CEA-based vaccines has generated a great deal of excitement, and yet he anticipates even more from the newer vaccine constructs. ..
  3. CEA BASED VACCINE THERAPY IN PATIENTS WITH ADVANCED CA
    John Marshall; Fiscal Year: 2003
    ..So far, the applicant's experience with the first generation CEA-based vaccines has generated a great deal of excitement, and yet he anticipates even more from the newer vaccine constructs. ..
  4. CEA BASED VACCINE THERAPY IN PATIENTS WITH ADVANCED CA
    John Marshall; Fiscal Year: 2004
    ..So far, the applicant's experience with the first generation CEA-based vaccines has generated a great deal of excitement, and yet he anticipates even more from the newer vaccine constructs. ..
  5. CEA BASED VACCINE THERAPY IN PATIENTS WITH ADVANCED CA
    John Marshall; Fiscal Year: 2005
    ..So far, the applicant's experience with the first generation CEA-based vaccines has generated a great deal of excitement, and yet he anticipates even more from the newer vaccine constructs. ..